Cardiovascular Diseases Clinical Trial
— LeguPlan_1Official title:
Acute Effects of Legume-enriched Meals Compared to Western Diet Meals on Postprandial Metabolic Response in Women and Men at Increased Risk of Cardiovascular and Neurodegenerative Diseases
Verified date | May 2024 |
Source | University of Bonn |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to investigate the postprandial effects of legume-enriched meals compared to Western Diet meals on postprandial metabolism. In this context, older adults with increased risk for cardiometabolic diseases consume 4 mixed meals with 36 g or 62 g of protein either designed according to the Planetary Health Diet with legumes as primary protein source or the Western Diet with animal foods as primary protein source, in a randomized order. In a postprandial observation period of 6 hours, parameters of lipid metabolism, glucose and insulin metabolism, amino acid profile, as well as markers of inflammation and vascular function are analysed. Furthermore, neuropsychological parameters and satiety-associated hormones are investigated.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | July 30, 2024 |
Est. primary completion date | July 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 75 Years |
Eligibility | Inclusion Criteria: - written informed consent - Non-smoking - BMI: 27 - 34,9 kg/m2 - Waist circumference (women = 80 cm, men = 94 cm) - Systolic blood pressure: = 120 mmHg, diastolic blood pressure: = 80 mmHg - At least one of the following criteria - Fasting triglycerides in serum: = 150 mg/dL - Fasting HDL-Cholesterol in serum: women < 50 mg/dl, men < 40 mg/dL - Fasting C-reactive protein in serum: = 2 mg/L - Fasting glucose in plasma: = 100 mg/dL Exclusion Criteria: - food intolerances and allergies (especially to legumes) - Smoking - malabsorption syndromes - thyroid diseases - impaired renal function - chronic liver disease - heart failure - myocardial infarction - insulin-dependent diabetes mellitus - chronic inflammatory diseases - tumors - anemia - immunosuppression - intake of supplements (e.g., fish oil) - Participation in another study - other exclusion criteria at the discretion of the physician/ investigator |
Country | Name | City | State |
---|---|---|---|
Germany | University of Bonn, Institute of Nutritional and Food Sciences, Nutrition Physiology | Bonn | North-Rhine Westphalia |
Lead Sponsor | Collaborator |
---|---|
University of Bonn | Federal Ministry of Food and Agriculture (BMEL), Federal Office for Agriculture and Food (BLE) |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Parameters of lipid metabolism in blood | Triglycerides (mg/dL) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of lipid metabolism in blood | Total cholesterol (mg/dL) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of lipid metabolism in blood | LDL cholesterol (mg/dL) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of lipid metabolism in blood | HDL cholesterol (mg/dL) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of lipid metabolism in blood | Free fatty acids (mmol/L) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of glucose metabolism in blood | Glucose (mg/dL) | Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours) | |
Secondary | Parameters of glucose metabolism in blood | Insulin (nmol/L) | Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours) | |
Secondary | Parameters of glucose metabolism in blood | cPeptide (pg/mL) | Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours) | |
Secondary | Parameters of glucose metabolism in blood | GLP-1 (pg/mL) | Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of glucose metabolism in blood | Glucagon (pg/mL) | Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours) | |
Secondary | Blood amino acid profile | Amino acid profile in blood (nmol/mL) | Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours) | |
Secondary | Blood urea | Urea in blood (mg/dL) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Uric acid in blood | Uric acid in blood (mg/dL) | Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of hunger and satiety in blood | e.g. Ghrelin (pg/mL) | Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of endothelial function in blood | e.g. ADMA (µmo/L) | Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours) | |
Secondary | Parameters of inflammation in blood | e.g. IL-6 (pg/mL) | Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours) | |
Secondary | Endothelial function | e.g. pulse wave velocity (m/s) | Postprandial period of 6 hours (T=0, 2, 4, 6 hours) | |
Secondary | Neuropsychological parameters | Assessment of hunger and satiety via a visual analogue scale (e.g. 0 = not hungry at all to 10 = very hungry) | Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours) | |
Secondary | Neuropsychological parameters | Assessment of attention via questionnaire (paper pencil test, e.g. higher amount of marked target items = higher attention, maximum points 640 = every target items marked correctly, minimum points: 0 = no target items marked or only wrong items marked) | Postprandial period of 4.5 hours (T= 0, 1.5, 3, 4.5 hours) | |
Secondary | Neuropsychological parameters | Assessment of memory via questionnaire (paper pencil, e.g. higher reproduction of memorised visual and verbal information = better memory; visual part: maximum points: 31 = all visual information memorised, minimum points: 0 = no visual information memorised; verbal part: maximum points: 24 = all verbal information memorised, minimum points: 0 = no verbal information memorised) | Postprandial period of 6 hours (T=0.5, 3, 6 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|